文献速递浆细胞疾病造血干细胞移植与细胞治疗

单药硼替佐米作为移植后巩固治疗对多发性骨髓瘤相关骨病的影响:一项随机II期研究

Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study.
PubMed 文献 · Br J Haematol · 2017-04-06

这项II期研究探讨了在自体干细胞移植后达到部分缓解或更好疗效的患者中,硼替佐米巩固治疗与观察对骨髓瘤相关骨病的影响。患者随机接受四个35天周期的硼替佐米1.6 mg/m2静脉注射(第1、8、15、22天)或等效观察期。改良意向治疗人群包括104例患者(硼替佐米组51例,观察组53例)。主要终点骨密度从基线至治疗结束的变化无有意义的差异。与观察相比,硼替佐米似乎对骨代谢/健康影响不大,但与骨髓瘤缓解和生存改善的趋势相关。

要点

  • 硼替佐米巩固组与观察组骨密度变化无有意义差异。
  • 治疗结束时完全缓解/严格完全缓解率硼替佐米组22% vs 观察组11%(P=0.19)。
  • 硼替佐米组腹泻、周围感觉神经病、恶心和呕吐发生率高于观察组。

核心结论

  • 与观察相比,硼替佐米似乎对骨代谢/健康影响不大,但与骨髓瘤缓解和生存改善的趋势相关。

研究设计与样本

  • 这项II期研究将前线高剂量治疗和自体干细胞移植后达到部分缓解或更好疗效的患者随机分配至硼替佐米巩固治疗组或观察组。
  • 硼替佐米组接受四个35天周期的硼替佐米1.6 mg/m2静脉注射,第1、8、15和22天给药;观察组接受等效观察期。
  • 改良意向治疗人群包括104例患者(硼替佐米组51例,观察组53例)。

主要发现

  • 主要终点骨密度从基线至治疗结束的变化无有意义的差异。
  • 治疗结束时完全缓解/严格完全缓解率硼替佐米组22% vs 观察组11%(P=0.19)。
  • 治疗结束时非常好的部分缓解或更好率硼替佐米组80% vs 观察组68%(P=0.17)。
  • 治疗结束时疾病进展率硼替佐米组8% vs 观察组23%(P=0.06)。
  • 中位无进展生存期硼替佐米组44.9个月 vs 观察组21.8个月(P=0.22)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This phase II study explored the effects of bortezomib consolidation versus observation on myeloma-related bone disease in patients who had a partial response or better after frontline high-dose therapy and autologous stem cell transplantation. Patients were randomized to receive four 35-day cycles of bortezomib 1·6 mg/m2 intravenously on days 1, 8, 15 and 22, or an equivalent observation period, and followed up for disease status/survival. The modified intent-to-treat population included 104 patients (51 bortezomib, 53 observation). There were no meaningful differences in the primary endpoint of change from baseline to end of treatment in bone mineral density (BMD). End-of-treatment rates (bortezomib versus observation) of complete response/stringent complete response were 22% vs. 11% (P = 0·19), very good partial response or better of 80% vs. 68% (P = 0·17), and progressive disease of 8% vs. 23% (P = 0·06); median progression-free survival was 44·9 months vs. 21·8 months (P = 0·22). Adverse events observed ≥15% more frequently with bortezomib versus observation were diarrhoea (37% vs. 0), peripheral sensory neuropathy (20% vs. 4%), nausea (18% vs. 0) and vomiting (16% vs. 0). Compared with observation, bortezomib appeared to have little impact on bone metabolism/health, but was associated with trends for improved myeloma response and survival.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Sezer O, Beksac M, Hajek R, et al. Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study. Br J Haematol. 2017. PMID: 28382618. doi:10.1111/bjh.14637

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。